Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients
Lee, Grace , Oladeru, Oluwadamilola T. , Niemierko, Andrzej , Haddock, Michael G. , Toesca, Diego A.S. , Koong, Amanda Jeanette , Owen, Dawn , Weekes, Colin D. , Hong, Theodore S. , Chang, Daniel T. , Hallemeier, Christopher L. , Wo, Jennifer Y. , Gergelis, Kimberly R. , Oladeru, Oluwadamilola T , Kim, Daniel W. , Hallemeier, Christopher Leigh

Mayo Clinic

Pancreas | May 21, 2021 | Volume: 50 | Issue: 5 | Pages: 736-743

10.1097/mpa.0000000000001822 | PMID 34016893 Get It

Objectives We evaluated the outcomes of metastatic pancreatic cancer (MPC) patients who underwent liver metastases (LMs)–directed ablative radiotherapy (RT) and sought to characterize patients with more favorable prognosis. Methods A retrospective analysis of 76 MPC patients who underwent ablative RT (median dose, 50 Gy) to LM at 3 academic centers between 2008 and 2018 was performed. Endpoints were local control (LC), progression-free survival, and overall survival (OS) since RT. Results Median follow-up was 10.9 months. Liver metastases were metachronous in 68%. Before RT, LM was responsive/stable on chemotherapy (CTX) in 36% whereas progressive in 43%. Median carbohydrate antigen 19-9 (CA 19-9) at RT was 334 U/mL. After RT, 32% had ≥6 months of CTX break. Twelve-month outcomes were: LC, 66%; progression-free survival, 7%; and OS, 38%. On multivariable analysis, Eastern Cooperative Oncology Group 2–3 (hazard ratio [HR], 13.49; P < 0.01), progressive LM on CTX (HR, 3.26; P < 0.01), and higher CA 19-9 (log 10 scale; HR, 1.39; P < 0.01) at RT predicted worse OS. Conclusions Ablative RT to LM in setting of MPC may offer LC of systemic disease and thus quality time off CTX. Selected patients with good performance status, stable/responsive LM on CTX, and lower CA 19-9 have more favorable prognosis.
Genetic and Clinical Studies of Patients With Increased Multinucleated Megakaryocytes in Bone Marrow as an Isolated Finding
Zheng, Gang , He, Rong , Reichard, Kaaren K. , Peterson, Jess F. , Olteanu, Horatiu , Oliveira, Jennifer L. , Rangan, Aruna , Chen, Dong , Herrick, Jennifer L. , Chen, Dong , Peterson, Jess F , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | May 19, 2021 | Volume: 45 | Issue: 11 | Pages: 1534-1540

10.1097/pas.0000000000001732 | PMID 33999554 Get It

The presence of increased multinucleated megakaryocytes (aka osteoclast-like) is considered a dysplastic feature in myelodysplastic syndrome; however, its clinical significance in isolation is uncertain. Herein, we report the clinicopathologic and genetic features of 18 such cases of 40,539 bone marrow biopsies spanning 10 years. All 18 patients had ≥25% multinucleated megakaryocytes in otherwise normal bone marrow biopsies, which were evaluated for plasma cell neoplasms (n=9), lymphoma (n=4), or anemia/neutropenia (n=5). None of the 17 patients tested showed acquired cytogenetic abnormalities. Sixteen patients underwent targeted gene panel next-generation sequencing: 9 patients had no pathogenic mutations; 3 harbored a single pathogenic mutation with variant allele frequencies of 7.5%, 7.6%, and 10.7%, likely representing clonal hematopoiesis of indeterminate potential; 1 had 2 pathogenic mutations, 1 of which had a variant allele frequency >20%. Fourteen of 18 patients had a follow-up period >6 months (median: 36.5 mo, range: 7 to 110 mo) and no patients developed a new-onset cytopenia, a progressive cytopenia, or a myeloid neoplasm. The patient with 2 mutations had persistent anemia, worrisome for an emerging MDS. However, given the absence of thrombocytopenia, increased multinucleated megakaryocytes in this patient could be an unrelated incidental finding. Our study indicates that increased multinucleated megakaryocytes as an isolated finding is a rare phenomenon, and this sole morphologic finding is not diagnostic of myelodysplastic syndrome. Diagnostic approaches in the presence of increased multinucleated megakaryocytes are proposed based on different clinical and pathologic scenarios.
Patient perceptions and use of non‐statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
Lowenstern, Angela , Li, Shuang , Návar, Ann Marie , Virani, Salim S. , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Kampman, Wendy, Wang, Tracy Y., Navar, Ann Marie , Peterson, Eric D.

Mayo Clinic

Clinical Cardiology | May 19, 2021 | Volume: 44 | Issue: 6 | Pages: 863-870

10.1002/clc.23625 | PMID 34008247 Get It

AbstractBackgroundNon‐statin lipid lowering therapies (LLTs) provide additional treatment options for patients. Use patterns and patient perceptions of non‐statin LLT remain incompletely described.HypothesisThe guideline‐recommended statin intensity remains underutilized in patients treated with and without non‐statin LLT.MethodsThe PALM Registry collected LLT information on patients with or at risk of ASCVD treated at 125 US clinics in 2015. We compared patient perceptions, lipid levels and statin use among patients treated with and without non‐statin LLT.ResultsAmong 7720 patients, 1930 (25.0%) were treated with a non‐statin LLT (1249 fish oil, 417 fibrates, 329 ezetimibe, 196 niacin). Concurrent statin treatment occurred in 73.7%, of which 45.4% were dosed under the guideline‐recommended intensity. Compared with patients on statin alone, patients receiving both a statin and non‐statin LLT (n = 1423) were more likely to be male, white race and to perceive themselves as higher risk of ASCVD compared with their peers (38.5% vs. 34.9%, p = .047). Only 27.4% of patients treated with non‐statin LLT alone perceived themselves at higher risk. Most (75.7%) patients treated with a non‐statin LLT alone reported never being treated with a statin, despite ASCVD in 30.8% of these patients. Among those previously treated with a statin, 59.3% reported being willing to try a statin again.ConclusionsNon‐statin LLT is used in one in four patients with or at risk for ASCVD; its use is frequently in place of statin therapy or in the absence of guideline‐recommended statin intensity. More work is needed to establish statins as first line therapy.
Abstract P103: Association Of Lipid Variability With Incident Alzheimers Disease And Alzheimers Disease Related Dementias
Moser, Ethan D. , Manemann, Sheila M., Rocca, Walter A. , Roger, Véronique L. , Decker, Paul A. , Killian, Jill M. , Moser, Ethan D , Larson, Nicholas B. , Sauver, Jennifer L. St. , Takahashi, Paul Y. , Mielke, Michelle M. , Olson, Janet E. , Decker, Paul A. , Bielinski, Suzette J.

Mayo Clinic

Circulation | May 18, 2021 | Volume: 143 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.143.suppl_1.p103 Get It

Background: Prevention strategies for Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRDs) are urgently needed for reducing incidence. Intra-patient variability in lipid levels is a potentially modifiable risk factor for incident AD/ADRD. Although regular lipid measurements are a part of common clinical practice and longitudinal data routinely available in electronic health records (EHR), research examining this association between AD/ADRD and lipid variability across multiple lipid types remains scarce. Methods: All residents living in Olmsted County, MN on 1/1/2006 age ≥60 years without an AD/ADRD diagnosis were identified using Centers for Medicare & Medicaid Services diagnostic codes. Persons with ≥3 lipid measurements (total cholesterol or triglycerides) in the 5 years prior to index date were retained. Lipid variability was quantified using variability independent of the mean (VIM). Models were adjusted for traditional risk factors. Associations between lipid variability quintiles and incident AD/ADRD were assessed using Cox proportional hazards regression. Multiple imputation was used for missing covariates. Participants were followed through 2018 for incident AD/ADRD. Results: The final analysis included data on 11,551 participants with total cholesterol and 11,502 participants with triglycerides. Participants had a mean age of 71 (range 60-99) years, and were primarily white (96%). Females (54%) were also slightly more frequent than males. Median follow up was 12.9 years (range: 0-13). Participants in the highest quintile of variability for total cholesterol and triglycerides had a 20% increased risk of incident AD/ADRD. Similar results were found in the subset with complete covariate data. Conclusion: In a large EHR derived cohort, persons in the highest quintile of lipid variation had an increased risk of incident AD/ADRD. Further studies to identify the mechanisms behind this risk factor and replication of these results across a more diverse population are needed.
Abstract P102: Variability In Lipid Levels And Risk For Cardiovascular Disease: An Electronic Health Record-based Population Cohort Study
Manemann, Sheila M., Moser, Ethan D. , Roger, Véronique L. , Decker, Paul A. , Killian, Jill M. , Moser, Ethan D , Bielinski, Suzette J. , Sauver, Jennifer L. St. , Takahashi, Paul Y. , Olson, Janet E. , Decker, Paul A. , Larson, Nicholas B.

Mayo Clinic

Circulation | May 18, 2021 | Volume: 143 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.143.suppl_1.p102 Get It

Background: Larger within-patient variability of lipid levels has been associated with an increased risk of cardiovascular disease (CVD). However, measures of lipid variability are not currently used clinically. We investigated the feasibility of calculating lipid variability within a large electronic health record (EHR)-based population cohort and assessed associations with incident CVD. Methods: We identified all individuals ≥40 years of age who resided in Olmsted County, MN on 1/1/2006 (index date) without prior CVD. CVD was defined as myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention or stroke. Patients with ≥3 measurements of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and/or triglycerides during the 5 years before the index date were retained in the analyses. Lipid variability was calculated using variability independent of the mean (VIM). Patients were followed through 9/30/2017 for incident CVD (including CVD death). Cox regression was used to investigate the association between quintiles of lipid VIMs and incident CVD. Results: We identified 18,642 individuals (mean age 60; 55% female) who were free of CVD at baseline and VIM calculated for at least one lipid measurement. After adjustment, those in the highest VIM quintiles of total cholesterol had a 25% increased risk of CVD (Q5 vs. Q1 HR: 1.25, 95% CI: 1.08-1.45; Table). We observed similar results for LDL-C (Q5 vs. Q1 HR: 1.20, 95% CI: 1.04-1.39) and HDL-C (Q5 vs. Q1 HR: 1.25, 95% CI: 1.09-1.43). There was no association between triglyceride variability quintiles and CVD risk. Conclusion: In a large EHR-based population cohort, high variability in total cholesterol, HDL-C and LDL-C was associated with an increased risk of CVD, independently of traditional risk factors, suggesting it may be a target for intervention. Lipid variability can be calculated in the EHR environment but more research is needed to determine its clinical utility.
Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis
Bajaj, Jasmohan S. , García‐Tsao, Guadalupe , Reddy, K. Rajender , O’Leary, Jacqueline G. , Vargas, Hugo E. , Kamath, Patrick S. , Subramanian, Ram, Thuluvath, Paul J. , Fagan, Andrew , Sehrawat, Tejasav S. , Rodríguez, Randolph de la Rosa, Sehrawat, Tejasav S , Wong, Florence , Vargas, Hugo E , García–Tsao, Guadalupe , Lai, Jennifer C. , Tandon, Puneeta , Thacker, Leroy R. , Wong, Florence

Mayo Clinic

Hepatology | May 18, 2021 | Volume: 74 | Issue: 5 | Pages: 2699-2713

10.1002/hep.31907 | PMID 34002868 Get It

Background and Aims Acute kidney injury (AKI) has a poor prognosis in cirrhosis. Given the variability of creatinine, the prediction of AKI and dialysis by other markers is needed. The aim of this study is to determine the role of serum and urine metabolomics in the prediction of AKI and dialysis in an inpatient cirrhosis cohort. Approach and Results Inpatients with cirrhosis from 11 North American Consortium of End‐stage Liver Disease centers who provided admission serum/urine when they were AKI and dialysis‐free were included. Analysis of covariance adjusted for demographics, infection, and cirrhosis severity was performed to identify metabolites that differed among patients (1) who developed AKI or not; (2) required dialysis or not; and/pr (3) within AKI subgroups who needed dialysis or not. We performed random forest and AUC analyses to identify specific metabolite(s) associated with outcomes. Logistic regression with clinical variables with/without metabolites was performed. A total of 602 patients gave serum (218 developed AKI, 80 needed dialysis) and 435 gave urine (164 developed AKI, 61 needed dialysis). For AKI prediction, clinical factor–adjusted AUC was 0.91 for serum and 0.88 for urine. Major metabolites such as uremic toxins (2,3‐dihydroxy‐5‐methylthio‐4‐pentenoic acid [DMTPA], N2N2dimethylguanosine, uridine/pseudouridine) and tryptophan/tyrosine metabolites (kynunerate, 8‐methoxykyunerate, quinolinate) were higher in patients who developed AKI. For dialysis prediction, clinical factor–adjusted AUC was 0.93 for serum and 0.91 for urine. Similar metabolites as AKI were altered here. For dialysis prediction in those with AKI, the AUC was 0.81 and 0.79 for serum/urine. Lower branched‐chain amino‐acid (BCAA) metabolites but higher cysteine, tryptophan, glutamate, and DMTPA were seen in patients with AKI needing dialysis. Serum/urine metabolites were additive to clinical variables for all outcomes. Conclusions Specific admission urinary and serum metabolites were significantly additive to clinical variables to predict AKI development and dialysis initiation in inpatients with cirrhosis. These observations can potentially facilitate earlier initiation of renoprotective measures.
Rapid Rise of Pediatric Telehealth During COVID-19 in a Large Multispecialty Health System
Howie, Flora, Kreofsky, Beth L. , Ravi, Anupama, Lokken, Troy G., Hoff, Mekenzie D., Fang, Jennifer L. , Lokken, Troy

Mayo Clinic

Telemedicine and e-Health | May 17, 2021 | Volume: 28 | Issue: 1 | Pages: 3-10

10.1089/tmj.2020.0562 | PMID 33999718 Get It

Background: Before the COVID-19 pandemic, telemedicine use for outpatient pediatric specialty care was low. Stay-at-home orders (SHO) prompted rapid upscaling of telemedicine capabilities and upskilling of providers. This study compares telemedicine usage before and after the SHO and analyzes how a Children's Center addressed challenges associated with a rapid rise in telemedicine. Methods: Data on outpatient visits across 14 specialty divisions were abstracted from the institutional electronic medical record. The 12-week study period (March 9, 2020–May 29, 2020) spanned three epochs: pre-SHO; post-SHO; reopening to in-person visits. Changes in in-person visits, video visits, and completed, cancelled, and no-show appointments were compared between three epochs. Results: A total of 4,914 outpatient pediatric specialty visits were completed, including 67% (3,296/4,914) in-person and 33% (1,618/4,914) through video. During the first two epochs encompassing the SHO, video visits increased by 4,750%. During the third epoch when the SHO was lifted, video visits decreased by 66%, with 19.4% of visits conducted through video in week 12. Overall, for outpatient video appointments, 82.8% (1,618/1,954) were completed, 9.1% (178/1,954) were cancelled, and 8.1% (158/1,954) were no-shows. The percentage of completed and no-show appointments did not differ between epochs. However, the cancellation rate decreased significantly from Epochs 1 to 3 (p = 0.008). Conclusion: A SHO was associated with a large increase in pediatric specialty video visits. Post-SHO, the percentage of pediatric specialty visits conducted through video decreased but remained higher than before the SHO. Frequent, content-rich communications, self-directed tutorials, and individualized coaching may facilitate successful increases in telemedicine use.
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly, Roisín M. , Leal, Jeffrey P. , Sólnes, Lilja B. , Huang, Chiung‐Yu , Carpenter, Ashley , Gaffney, Katy, Abramson, Vandana G. , Carey, Lisa A. , Liu, Minetta C. , Rimawi, Mothaffar F. , Specht, Jennifer M. , Storniolo, Anna Maria , Valero, Vicente , Krop, Ian E. , Camp, Melissa , Miller, Robert S. , Cimino‐Mathews, Ashley , Stearns, Vered , Abramson, Vandana G , Rimawi, Mothaffar , Specht, Jennifer , Vaklavas, Christos , Krop, Ian E , Winer, Eric , Miller, Robert S , Wolff, Antonio C , Cimino-Mathews, Ashley , Park, Ben Ho , Wahl, Richard L , Stearns, Vered , Carey, Lisa A , Huang, Chiung-Yu , Gaffney, Katy, Winer, Eric P. , Wolff, Antonio C. , Wahl, Richard L.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2021 | Volume: 39 | Issue: 20 | Pages: 2247-2256

10.1200/jco.21.00280 | PMID 33999652 Get It

PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT). PATIENTS AND METHODS Patients with stage II or III, estrogen receptor–negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by C1D15 predicting pCR is ≤ 0.65, with a one-sided type I error rate of 10%. RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P = .12), which did not reject the null hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P = .004) and SULmax reduction ≥ 40% was more prevalent (83% v 52%; P = .03; positive predictive value, 31%). Participants not obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%). CONCLUSION Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor–negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
Abstract 16983: Validation of 3D Volume Measurement Technology to Assess Body Fat Content Using Biplane Imaging From Mobile Devices
Suarez, Audry Chacin, Saeidifard, Farzane , Gowda, Smitha Narayana , Robinson, Justin A., Aseged, Kalkidan, Lynne, Johnson, Zundel, Jennifer, Bonikowske, Amanda R. , Medina‐Inojosa, José R. , Chacin‐Suarez, Audry , López-Jiménez, Francisco

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.16983 Get It

Introduction: Body fat (BF) content better predicts adiposity-related cardiovascular risk than the body mass index (BMI). Accurate and accepted methods to assess BF are complex, expensive, and accessible only in clinical settings. Multi-sensor 3D body volume (3D-BV) measurement technology has been shown to accurately estimate BF. We assessed the hypothesis that 3D models generated from biplane imaging (i.e., front and side facing photographs) using mobile devices (App), could be used to predict body volume measurements and derive BF. Methods: We prospectively enrolled 196 subjects, who underwent 3D-BV (gold standard for body volume) within 24 hours, dual-energy X-ray Absorptiometry (iDEXA) (gold standard for BF) and photographs taken with an Ipad® App at a predefined distance and pose. These photos were post-processed with a computer-assisted algorithm to estimate body length, girth, and volume. These were used to calculate body density (BD) using the bicompartmental principles of body composition (BD=Body Mass/Volume) and derive BF% using the Siri equation [(4.95/BD-4.50) X 100]. Correlation indexes and residual plots were created to compare 3D-BV and iDEXA with the App. Mean differences were compared using a paired t-test. Results: Mean ±SD age was 31.9±9.15 years, 53% were women, weight 72.8±14.1 kg, BMI was 25.5±4.5 kg/m 2 .The App volume correlated with 3D-BV (R 2 =0.95,95%CI 0.90,0.95, p<.0001, Figure 1-A ) ; average difference between App volume vs 3D-BV volume was -1.2 Liters, 95%CI,0.03, 2.42, p=0.06, ( Figure 1-B ). App BF% correlated with iDEXA BF% (R 2 =0.92, 95%CI 0.90,0.94, p<.0001, Figure 1-C ) ; while average difference between App BF% vs iDEXA BF% was -0.13 %, 95%CI -0.6,0.4, p=0.6, ( Figure 1-D ). Conclusion: BF can be estimated using volume measurements obtained by biplane imaging from mobile devices and could serve as a home-based, portable, scalable, cost-effective, and convenient measure to assess BF and track changes in body composition over time.